The role and efficacy of efavirenz/emtricitabine/tenofovir (EFV+FTC+TDF, Viraday)

Efavirenz/Emtricitabine/Tenofovir (EFV+FTC+TDF, Viraday) is a single fixed-dose combination tablet that contains three active substances that can keep immunodeficiency syndrome (AIDS) levels in the blood at low levels. It does not cure HIV infection or AIDS, but it can prevent damage to the immune system and the development of AIDS-related infections and diseases.

Efavirenz, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI); emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoprost, which is a "prodrug" of tenofovir, meaning it is converted into the active substance tenofovir in the body. Tenofovir is a nucleotide reverse transcriptase inhibitor. Nucleoside and nucleotide reverse transcriptase inhibitors are commonly known as NRTIs. All three active substances block the activity of reverse transcriptase, an enzyme that allows HIV to multiply itself in the cells it infects. Current treatment guidelines recommend this triple combination for initial treatment because of its excellent efficacy, tolerability, and favorable safety profile. Individually, these drugs have long half-lives, allowing once-daily dosing.

Efavirenz/Emtricitabine/Tenofovir (Viraday) is not currently on the market in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase it through overseas purchasing channels. The cheaper ones abroad are mainly Indian generic drugs, whose drug ingredients are basically the same as those of the original drugs. The price of each box of specifications (600MG+200MG+300MG)*30 may be more than 300 yuan (the price may fluctuate due to the exchange rate). For specific drug prices and drug information, please consult Yaode Medical Consultant.